loader
Please Wait
Applying Filters...
pipeline-prospector-insert
X

List of Active Pharmaceutical Ingredient (API) suppliers/manufacturers & exporters

LISTED SUPPLIERS

Filters Filter
×
FILTER DATA :

filter

Abacavir Sulfate

Adefovir Dipivoxil

Alfacalcidol

Aliskiren Fumarate

Amidopyrine

Aminophylline

Amobarbital Sodium

Amoxapine

Amphotericin B

Apixaban

Aripiprazole

Atazanavir Sulfate

Atorvastatin

Atropine Sulfate

Azacitidine

BACITRACIN ZINC

Bacitracin

Bazedoxifene

Bosentan

Buprenorphine

Buprenorphine Hydrochloride

Caffeine

Calcium Carbonate

Carvedilol Phosphate

Cefdinir

Cefditoren Pivoxil

Cefpodoxime Pivoxil

Cetirizine Dihydrochloride

Chlorazepate dipotassium

Cholic Acid

Cinacalcet Hydrochloride

Cinacelcet hydrochloride

Citicoline Sodium

Clopidogrel Bisulfate

Colchicine

DABIGATRAN ETEXILATE MESYLATE

Daptomycin

Darunavir

Dasatinib Hydrate

Dehydroepiandrosterone

Digoxin

Dimethyl Fumarate

Entecavir

Epinastine HCL

Erlotinib HCL

Estazolam

FLUPENTIXOL DIHYDROCHLORIDE

FLUPHENAZINE HCL

Fampridine

Fexofenadine Hydrochloride

Fluconazole

Flunitrazepam

Fluorouracil

Fluoxetine Hydrochloride

Flurazepam Monohydrochloride

Fluticasone Propionate

Fluvastatin Sodium

Fluvoxamine

Formoterol

Furosemide

Gabapentin

Gadodiamide

Galanthamine

Gefitinib

Gemcitabine

Gemfibrozil

Gimeracil-13C3

Gliclazide

Glimepiride

Gramicidin

Haloperidol

Haloperidol Decanoate

Heparin

Hydrochlorothiazide

Hydrocortisone Acetate

IBANDRONATE SODIUM

IMATINIB MESYLATE

Idarubicin

Imatinib Mesylate

Imipramine

Imiquimod

Insulin

Irbesartan

Irinotecan

Irinotecan HCL

Itopride HCL

Itraconazole

LOSARTAN POTASSIUM

LOXAPINE SUCCINATE

Lamivudine

Lenalidomide

Linagliptin

Lormetazepam

Loxapine HCl

MOMETASONE FUROATE MONOHYDRATE

MONTELUKAST SODIUM

Maxacalcitol

Meloxicam

Memantine HCL

Metol

Metopimazine

Mometasone Furoate

Mosapride Citrate

Nilotinib HCL

Nimodipine

Norepinephrine bitartrate

Olmesartan Medoxomil

Omeprazole Magnesium

Oteracil potassium

Oxaliplatin

PAZOPANIB HYDROCHLORIDE

Paclitaxel

Pancreatin

Paracetamol

Pemetrexed Sodium

Pindolol

Pioglitazone HCL

Pipemidic Acid

Pirfenidone

Prasugrel HCl

Prazepam

Propiomazine maleate

RABEPRAZOLE SDOIUM

Raloxifene

Rebamipide

Rifaximin

Risperidone

Rivaroxaban

Rosuvastatin

Rufinamide

Salicylic Acid

Silodosin

Sitagliptin Phosphate

Solifenacin Succinate

Sorafenib

Sterile Cefmetazole Sodium

Sterile Cefotetan Sodium

Sterile Cilastatin Sodium

Sterile Doripenem

Sterile Ertapenem

Sterile Imipenem

Sterile Imipenem/ Cilastatin Sodium

Sterile Latamoxef sodium

Sterile Meropenem

Sucralfate

Sulfo butyl ether beta Cyclodextrin Sodium

Sunitinib Malate

TALTIRELIN

TERIFLUNOMIDE

TOREMIFENE CITRATE

Tafluprost

Tamoxifen Citrate

Tamsulosin Hydrochloride

Tazarotene

Tegafur

Tenofovir Disoproxil

Tenofovir Disproxil

Testosterone

Tetracycline

Tetrahydrozoline

Ticagrelor

Timolol

Timolol Maleate

Tramadol Hydrochloride

Tranexamic Acid

Trimeprazine Tartrate

Troxerutin

Ulipristal

Valsartan

Vildagliptin

Voriconazole

Zaleplon

beta-cyclodextrin

brimonidine tartrate

cetilistat

clotiazepam

ethyl loflazepate

etizolam

fludiazepam

hydroxypropyl-beta cyclodextrin

levocetirizine dihydrochloride

melitracene hydrochloride

pitofenone hydrochloride

saxagliptin

tiemonium iodide

filter

BRAZIL

CHINA

DENMARK

FRANCE

INDIA

ISRAEL

ITALY

KOREA, REPUBLIC OF

TAIWAN

UNITED STATES

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Granules is a fast-growing pharmaceutical company with world-class manufacturing facilities in India and China and with offices in India, U.S., U.K., China and Colombia. The company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) that are marketed to quality-conscious cus...
Granules is a fast-growing pharmaceutical company with world-class manufacturing facilities in India and China and with offices in India, U.S., U.K., China and Colombia. The company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) that are marketed to quality-conscious customers in the regulated and semi-regulated global markets.The company services the growing needs of more than 300 customers across 60 nations.The company has its own ANDAs and dossiers, making it possible for customers to enter regulated markets with high-quality and cost-effective products.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of Flag Korea, Republic Of


Post An Enquiry Post An Enquiry


Virtual Booth Virtual Booth

Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to g...
Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to general, special, and aseptic pharmaceuticals.On the other hands, JEIL is manufacturing FDF Products sold to Japan and other countries.With marketing strategy of 'First generic' and Innovative drug, JEIL have been extended the market in world-wide.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Formosa Laboratories, Inc. produces APIs and UV-filters in its modern facilities near Taipei. Its GMP compliance has been approved by DOH of Taiwan, US FDA, BGV of Germany, EDQM and PMDA of Japan. Formosa’s major API products include Vitamin D derivatives (Alfacalcidol, Calcitriol, Calcipotriol, Doxercalciferol, and Paricalcitol), Balsalazide, Be...
Formosa Laboratories, Inc. produces APIs and UV-filters in its modern facilities near Taipei. Its GMP compliance has been approved by DOH of Taiwan, US FDA, BGV of Germany, EDQM and PMDA of Japan. Formosa’s major API products include Vitamin D derivatives (Alfacalcidol, Calcitriol, Calcipotriol, Doxercalciferol, and Paricalcitol), Balsalazide, Benzonatate, Capsaicin, Colesevelam, Gadodiamide, Flupentixol, Melitracen, Meprobamate, Montelukast, Mycophenolate Mofetil, Sevelamer (HCl and Carbonate), and Taltirelin. As a major producer in the world, our UV-filter products include avobenzone and Octinoxate. We also provide custom synthesis service from process development to full commercial production for APIs and other specialty chemicals, with full documentation support.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of Flag Korea, Republic Of


Post An Enquiry Post An Enquiry


Virtual Booth Virtual Booth

Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to g...
Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to general, special, and aseptic pharmaceuticals.On the other hands, JEIL is manufacturing FDF Products sold to Japan and other countries.With marketing strategy of 'First generic' and Innovative drug, JEIL have been extended the market in world-wide.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Established in 1943 as one of the national largest manufacturing and exporting bases in the chemical synthetic pharmaceuticals field, Shandong Xinhua Pharmaceutical Company Limited ("Shandong Xinhua") is in an leading position in the manufacturing technology and capacity for antipyretics and analgesics in China and is an important manufacturer in C...
Established in 1943 as one of the national largest manufacturing and exporting bases in the chemical synthetic pharmaceuticals field, Shandong Xinhua Pharmaceutical Company Limited ("Shandong Xinhua") is in an leading position in the manufacturing technology and capacity for antipyretics and analgesics in China and is an important manufacturer in China for the drugs for central nervous system, steroids, cardio cerebrovascular system as well as finished dosage forms and pharmaceutical intermediates. With implementing the global market development strategy and adopting the international advanced standards in quality management, Shandong Xinhua has been granted the certifications of GMP, ISO9001, ISO14001, ISO 10012, and ISO22000. The main products of Shandong Xinhua have been granted the COS Certificate from EDQM and passed the site inspection from USA FDA. By taking the advantages of its solid scientific research strength, well-established quality system, high market reputation as well as being a listing company of H shares and A shares with sound capital structure and product portfolio. "XINHUA" brand was honored with the title of "Chinese Famous Brand" in China. With the high commitment to the product quality and development of the international markets, the Company has established the strategic partnership with dozens of MNCs, the products of the Company has been distributed to more than 60 countries and regions.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Established in 1943 as one of the national largest manufacturing and exporting bases in the chemical synthetic pharmaceuticals field, Shandong Xinhua Pharmaceutical Company Limited ("Shandong Xinhua") is in an leading position in the manufacturing technology and capacity for antipyretics and analgesics in China and is an important manufacturer in C...
Established in 1943 as one of the national largest manufacturing and exporting bases in the chemical synthetic pharmaceuticals field, Shandong Xinhua Pharmaceutical Company Limited ("Shandong Xinhua") is in an leading position in the manufacturing technology and capacity for antipyretics and analgesics in China and is an important manufacturer in China for the drugs for central nervous system, steroids, cardio cerebrovascular system as well as finished dosage forms and pharmaceutical intermediates. With implementing the global market development strategy and adopting the international advanced standards in quality management, Shandong Xinhua has been granted the certifications of GMP, ISO9001, ISO14001, ISO 10012, and ISO22000. The main products of Shandong Xinhua have been granted the COS Certificate from EDQM and passed the site inspection from USA FDA. By taking the advantages of its solid scientific research strength, well-established quality system, high market reputation as well as being a listing company of H shares and A shares with sound capital structure and product portfolio. "XINHUA" brand was honored with the title of "Chinese Famous Brand" in China. With the high commitment to the product quality and development of the international markets, the Company has established the strategic partnership with dozens of MNCs, the products of the Company has been distributed to more than 60 countries and regions.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Established in 1943 as one of the national largest manufacturing and exporting bases in the chemical synthetic pharmaceuticals field, Shandong Xinhua Pharmaceutical Company Limited ("Shandong Xinhua") is in an leading position in the manufacturing technology and capacity for antipyretics and analgesics in China and is an important manufacturer in C...
Established in 1943 as one of the national largest manufacturing and exporting bases in the chemical synthetic pharmaceuticals field, Shandong Xinhua Pharmaceutical Company Limited ("Shandong Xinhua") is in an leading position in the manufacturing technology and capacity for antipyretics and analgesics in China and is an important manufacturer in China for the drugs for central nervous system, steroids, cardio cerebrovascular system as well as finished dosage forms and pharmaceutical intermediates. With implementing the global market development strategy and adopting the international advanced standards in quality management, Shandong Xinhua has been granted the certifications of GMP, ISO9001, ISO14001, ISO 10012, and ISO22000. The main products of Shandong Xinhua have been granted the COS Certificate from EDQM and passed the site inspection from USA FDA. By taking the advantages of its solid scientific research strength, well-established quality system, high market reputation as well as being a listing company of H shares and A shares with sound capital structure and product portfolio. "XINHUA" brand was honored with the title of "Chinese Famous Brand" in China. With the high commitment to the product quality and development of the international markets, the Company has established the strategic partnership with dozens of MNCs, the products of the Company has been distributed to more than 60 countries and regions.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Centaur accepts change as a constant, and continuously innovates to remain significant. Centaur has built knowledge sharing relationships with the pharmaceutical majors in areas of product development, custom synthesis, contract research and contract manufacturing. Centaur formulations and API are exported across 5 continents and more than 60 count...
Centaur accepts change as a constant, and continuously innovates to remain significant. Centaur has built knowledge sharing relationships with the pharmaceutical majors in areas of product development, custom synthesis, contract research and contract manufacturing. Centaur formulations and API are exported across 5 continents and more than 60 countries including regulated markets. Formulations Centaur ranks among India's TOP 50 pharmaceutical companies by prescriptions (CMarc) and by stockist audit (ORG-IMS). Centaur's All-India network includes a 1000 strong sales force that covers 250,000 doctors and 250,000 retailers every month. Over 50 million prescriptions of Centaur brands are generated by doctors of all specialities, annually. Prescription audits (ORG-IMS & CMarc) confirm that Sinarest is a clear leader in the Indian Anti-Cold market. One prescription of Sinarest is generated every second by a doctor in India! Centaur has demonstrated its competence in transforming products into strong brands, reinforced by successful extensions, resulting in a formidable presence in key therapy areas. Centaur brands are leaders in six therapeutic segments and rank among the top 3 in six other therapeutic segments. Centaur's manufacturing facilities at GOA conform to WHO-GMP standards, and dosage forms include tablets liquids, injectables (vials and ampoules), eye and ear drops, and ointments. CRAM The current pharma scenario has driven a shift, away from in-house R&D and production to contract research and manufacturing (CRAM). A fully scalable 25,000 square metres formulations facility conforming to USFDA / EU standards has been set up in Pune with a focus on oral solids. API Centaur is India's largest manufacturer and exporter of Psychotropic API and have introduced 24 API for the first time in India. Our API manufacturing facility near Mumbai conforms to USFDA standards and our clientele includes Big Pharma, generic majors and Indian multinationals. Our specialisation ranges from API and intermediates to custom synthesis and process chemistry. An integrated approach ensures that we can scale up capabilities from conceptualisation to commercialisation. CRO A 10,000 square feet, ultra-modern, contract research organisation (CRO) with a 36 bed clinical pharmacology unit (CPU), has been set up at Centaur House, our corporate headquarters. Facilities include Bio-availability (BA), Bio-equivalence (BE), Bio-analysis & Clinical trials. State-of-the-art R&D laboratories dedicated to formulations and API, approved by the Government of India are also located at Centaur House. Future By strategically positioning itself for collaborative relationships, Centaur has tied up with the world's leading players, by offering high performance value options and critical capabilities. We believe that our core competencies in API, formulations, CRAM and CRO will enhance business volumes and help us ascend the pharmaceutical value chain. This would help us realise our vision of emerging as a 'fully integrated global pharmaceutical player'.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Synbiotics Limited is a Public Company incorporated on 25 October 1960. It is classified as Indian Non-Government Company and is registered at Registrar of Companies, Ahmedabad. Its authorized share capital is Rs. 125,000,000 and its paid up capital is Rs. 84,446,000. Synbiotics Limited's Annual General Meeting (AGM) was last held on 30 September ...
Synbiotics Limited is a Public Company incorporated on 25 October 1960. It is classified as Indian Non-Government Company and is registered at Registrar of Companies, Ahmedabad. Its authorized share capital is Rs. 125,000,000 and its paid up capital is Rs. 84,446,000. Synbiotics Limited's Annual General Meeting (AGM) was last held on 30 September 2014 and as per records from Ministry of Corporate Affairs (MCA), its balance sheet was last filed on 31 March 2014. Directors of Synbiotics Limited are Mohal Kartikeya Sarabhai, Rajiv Mohjit Dhru and Gulammohiyuddin Abdulrahim Tamam.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Synbiotics Limited is a Public Company incorporated on 25 October 1960. It is classified as Indian Non-Government Company and is registered at Registrar of Companies, Ahmedabad. Its authorized share capital is Rs. 125,000,000 and its paid up capital is Rs. 84,446,000. Synbiotics Limited's Annual General Meeting (AGM) was last held on 30 September ...
Synbiotics Limited is a Public Company incorporated on 25 October 1960. It is classified as Indian Non-Government Company and is registered at Registrar of Companies, Ahmedabad. Its authorized share capital is Rs. 125,000,000 and its paid up capital is Rs. 84,446,000. Synbiotics Limited's Annual General Meeting (AGM) was last held on 30 September 2014 and as per records from Ministry of Corporate Affairs (MCA), its balance sheet was last filed on 31 March 2014. Directors of Synbiotics Limited are Mohal Kartikeya Sarabhai, Rajiv Mohjit Dhru and Gulammohiyuddin Abdulrahim Tamam.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Centaur accepts change as a constant, and continuously innovates to remain significant. Centaur has built knowledge sharing relationships with the pharmaceutical majors in areas of product development, custom synthesis, contract research and contract manufacturing. Centaur formulations and API are exported across 5 continents and more than 60 count...
Centaur accepts change as a constant, and continuously innovates to remain significant. Centaur has built knowledge sharing relationships with the pharmaceutical majors in areas of product development, custom synthesis, contract research and contract manufacturing. Centaur formulations and API are exported across 5 continents and more than 60 countries including regulated markets. Formulations Centaur ranks among India's TOP 50 pharmaceutical companies by prescriptions (CMarc) and by stockist audit (ORG-IMS). Centaur's All-India network includes a 1000 strong sales force that covers 250,000 doctors and 250,000 retailers every month. Over 50 million prescriptions of Centaur brands are generated by doctors of all specialities, annually. Prescription audits (ORG-IMS & CMarc) confirm that Sinarest is a clear leader in the Indian Anti-Cold market. One prescription of Sinarest is generated every second by a doctor in India! Centaur has demonstrated its competence in transforming products into strong brands, reinforced by successful extensions, resulting in a formidable presence in key therapy areas. Centaur brands are leaders in six therapeutic segments and rank among the top 3 in six other therapeutic segments. Centaur's manufacturing facilities at GOA conform to WHO-GMP standards, and dosage forms include tablets liquids, injectables (vials and ampoules), eye and ear drops, and ointments. CRAM The current pharma scenario has driven a shift, away from in-house R&D and production to contract research and manufacturing (CRAM). A fully scalable 25,000 square metres formulations facility conforming to USFDA / EU standards has been set up in Pune with a focus on oral solids. API Centaur is India's largest manufacturer and exporter of Psychotropic API and have introduced 24 API for the first time in India. Our API manufacturing facility near Mumbai conforms to USFDA standards and our clientele includes Big Pharma, generic majors and Indian multinationals. Our specialisation ranges from API and intermediates to custom synthesis and process chemistry. An integrated approach ensures that we can scale up capabilities from conceptualisation to commercialisation. CRO A 10,000 square feet, ultra-modern, contract research organisation (CRO) with a 36 bed clinical pharmacology unit (CPU), has been set up at Centaur House, our corporate headquarters. Facilities include Bio-availability (BA), Bio-equivalence (BE), Bio-analysis & Clinical trials. State-of-the-art R&D laboratories dedicated to formulations and API, approved by the Government of India are also located at Centaur House. Future By strategically positioning itself for collaborative relationships, Centaur has tied up with the world's leading players, by offering high performance value options and critical capabilities. We believe that our core competencies in API, formulations, CRAM and CRO will enhance business volumes and help us ascend the pharmaceutical value chain. This would help us realise our vision of emerging as a 'fully integrated global pharmaceutical player'.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of Flag Korea, Republic Of


Post An Enquiry Post An Enquiry


Virtual Booth Virtual Booth

Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to g...
Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to general, special, and aseptic pharmaceuticals.On the other hands, JEIL is manufacturing FDF Products sold to Japan and other countries.With marketing strategy of 'First generic' and Innovative drug, JEIL have been extended the market in world-wide.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Granules is a fast-growing pharmaceutical company with world-class manufacturing facilities in India and China and with offices in India, U.S., U.K., China and Colombia. The company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) that are marketed to quality-conscious cus...
Granules is a fast-growing pharmaceutical company with world-class manufacturing facilities in India and China and with offices in India, U.S., U.K., China and Colombia. The company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) that are marketed to quality-conscious customers in the regulated and semi-regulated global markets.The company services the growing needs of more than 300 customers across 60 nations.The company has its own ANDAs and dossiers, making it possible for customers to enter regulated markets with high-quality and cost-effective products.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of Flag Korea, Republic Of


Post An Enquiry Post An Enquiry


Virtual Booth Virtual Booth

Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to g...
Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to general, special, and aseptic pharmaceuticals.On the other hands, JEIL is manufacturing FDF Products sold to Japan and other countries.With marketing strategy of 'First generic' and Innovative drug, JEIL have been extended the market in world-wide.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Resonance has been a presence in the API and Specialty Chemicals segment for more than 30 years. After a start in Mumbai, operations moved to Bangalore in 1984. In the 30 years, Resonance has partnered with several multinationals on custom synthesis projects and with our strengths in multi-step synthesis together with focus on quality, we have help...
Resonance has been a presence in the API and Specialty Chemicals segment for more than 30 years. After a start in Mumbai, operations moved to Bangalore in 1984. In the 30 years, Resonance has partnered with several multinationals on custom synthesis projects and with our strengths in multi-step synthesis together with focus on quality, we have helped our customers develop their products in a timely fashion. We have brought the same discipline to our API business and in the recent years have developed some complex molecules that are produced in our cGMP plant. Our facility is WHO GMP certified and we follow cGMP as per the ICH Q7 guideline.We have registered DMFs and CEPs for some of our products and are in the process of registering more. We currently sell to the European and other markets on the basis of our DMFs and CEPs.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of Flag Korea, Republic Of


Post An Enquiry Post An Enquiry


Virtual Booth Virtual Booth

Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to g...
Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to general, special, and aseptic pharmaceuticals.On the other hands, JEIL is manufacturing FDF Products sold to Japan and other countries.With marketing strategy of 'First generic' and Innovative drug, JEIL have been extended the market in world-wide.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing clinically effective anti-infective treatments against serious and often life-threatening infections. With over 100 years of pharmaceutical industry expertise, we are a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharma...
Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing clinically effective anti-infective treatments against serious and often life-threatening infections. With over 100 years of pharmaceutical industry expertise, we are a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and finished dosage forms (FDF), and the world-leading supplier of Vancomycin and Colistimethate Sodium (CMS). Our range of anti-infective treatments combat, most types of bacterial and antibiotic-resistant infections and certain fungal diseases. We have growing sales in more than 70 countries to over 700 customers and are continually developing and expanding our product range to meet new treatment needs and to better service our customers’ requirements. This includes developing new dosage forms using Xellia’s APIs, and if required APIs sourced from our network of suppliers. To complement our dry powder fill and freeze-dried vials for injectable delivery we are also developing innovative proprietary delivery systems and formulations for topical, inhaled or injectable administration either in house or through partnerships. We also offer contract manufacturing services and custom synthesis for clinical trial material supply. Xellia is a private company, with more than 850 employees and three state-of-the-art manufacturing facilities Denmark, Hungary and China. We operate according to current Good Manufacturing Practice (cGMP) and our facilities have received regulatory approval from all relevant authorities, including the US Food and Drug Administration (FDA). Our operational headquarters are in Copenhagen, Denmark.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing clinically effective anti-infective treatments against serious and often life-threatening infections. With over 100 years of pharmaceutical industry expertise, we are a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharma...
Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing clinically effective anti-infective treatments against serious and often life-threatening infections. With over 100 years of pharmaceutical industry expertise, we are a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and finished dosage forms (FDF), and the world-leading supplier of Vancomycin and Colistimethate Sodium (CMS). Our range of anti-infective treatments combat, most types of bacterial and antibiotic-resistant infections and certain fungal diseases. We have growing sales in more than 70 countries to over 700 customers and are continually developing and expanding our product range to meet new treatment needs and to better service our customers’ requirements. This includes developing new dosage forms using Xellia’s APIs, and if required APIs sourced from our network of suppliers. To complement our dry powder fill and freeze-dried vials for injectable delivery we are also developing innovative proprietary delivery systems and formulations for topical, inhaled or injectable administration either in house or through partnerships. We also offer contract manufacturing services and custom synthesis for clinical trial material supply. Xellia is a private company, with more than 850 employees and three state-of-the-art manufacturing facilities Denmark, Hungary and China. We operate according to current Good Manufacturing Practice (cGMP) and our facilities have received regulatory approval from all relevant authorities, including the US Food and Drug Administration (FDA). Our operational headquarters are in Copenhagen, Denmark.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of Flag Korea, Republic Of


Post An Enquiry Post An Enquiry


Virtual Booth Virtual Booth

Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to g...
Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to general, special, and aseptic pharmaceuticals.On the other hands, JEIL is manufacturing FDF Products sold to Japan and other countries.With marketing strategy of 'First generic' and Innovative drug, JEIL have been extended the market in world-wide.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Zibo Qianhui Biological Technology Co., LTD is pharmaceutical and chemical industry enterprise allied with Shandong University, Shenyang Pharmaceutical University jointly organize scientific research and production . The company is located in Zibo high-tech district medicine industrial park, with modern testing center, the domestic most advanced ...
Zibo Qianhui Biological Technology Co., LTD is pharmaceutical and chemical industry enterprise allied with Shandong University, Shenyang Pharmaceutical University jointly organize scientific research and production . The company is located in Zibo high-tech district medicine industrial park, with modern testing center, the domestic most advanced pharmaceutical raw materials production line: Beta Cyclodextrin, Hydroxypropyl Beta Cyclodextrin, Hydroxyethyl Beta Cyclodextrin, Methyl Beta Cyclodextrin, Piroxicam Beta Cyclodextrin, Sulfo butyl ether beta Cyclodextrin Sodium, Glucose beta Cyclodextrin production line, has obtained the pharmaceutical production license and Hydroxypropyl Beta Cyclodextrin drug registration number.It is the earliest, the most advanced technology and the largest manufacturer of Hydroxypropyl Beta Cyclodextrin in China. Zibo Qianhui Biological Technology Co., Ltd is a pharmaceutical and chemical corporation integrating research and manufacture, which is associated with Shandong University and Shenyang Pharmaceutical University. Our firm lies in Pharmaceutical Industrial Park of Zibo High-Tech District. There are 60 staff members in our company, including 5 professors and 30 technicians. We have a modernized inspection center and the most advanced medical auxiliary production lines in China for Beta-Cyclodextrin, Hydroxypropyl-Beta-Cyclodextrin, Hydroxyethyl-Beta-Cyclodextrin, Methyl-Beta-Cyclodextrin, Piroxicam-Beta-Cyclodextrin, Sodiumsulphobutylether-Beta-Cyclodextrin and Glucosyl-Beta-Cyclodextrin. We are the earliest and most advanced factory which produces Hydroxypropyl-Beta-Cyclodextrin professionally in China. Guided by the spirit of being in good faith, our company is dedicated to extending sincere cooperation with you and making joint efforts and progress, thus achieving great accomplishments at an international level.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of Flag Korea, Republic Of


Post An Enquiry Post An Enquiry


Virtual Booth Virtual Booth

Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to g...
Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to general, special, and aseptic pharmaceuticals.On the other hands, JEIL is manufacturing FDF Products sold to Japan and other countries.With marketing strategy of 'First generic' and Innovative drug, JEIL have been extended the market in world-wide.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Centaur accepts change as a constant, and continuously innovates to remain significant. Centaur has built knowledge sharing relationships with the pharmaceutical majors in areas of product development, custom synthesis, contract research and contract manufacturing. Centaur formulations and API are exported across 5 continents and more than 60 count...
Centaur accepts change as a constant, and continuously innovates to remain significant. Centaur has built knowledge sharing relationships with the pharmaceutical majors in areas of product development, custom synthesis, contract research and contract manufacturing. Centaur formulations and API are exported across 5 continents and more than 60 countries including regulated markets. Formulations Centaur ranks among India's TOP 50 pharmaceutical companies by prescriptions (CMarc) and by stockist audit (ORG-IMS). Centaur's All-India network includes a 1000 strong sales force that covers 250,000 doctors and 250,000 retailers every month. Over 50 million prescriptions of Centaur brands are generated by doctors of all specialities, annually. Prescription audits (ORG-IMS & CMarc) confirm that Sinarest is a clear leader in the Indian Anti-Cold market. One prescription of Sinarest is generated every second by a doctor in India! Centaur has demonstrated its competence in transforming products into strong brands, reinforced by successful extensions, resulting in a formidable presence in key therapy areas. Centaur brands are leaders in six therapeutic segments and rank among the top 3 in six other therapeutic segments. Centaur's manufacturing facilities at GOA conform to WHO-GMP standards, and dosage forms include tablets liquids, injectables (vials and ampoules), eye and ear drops, and ointments. CRAM The current pharma scenario has driven a shift, away from in-house R&D and production to contract research and manufacturing (CRAM). A fully scalable 25,000 square metres formulations facility conforming to USFDA / EU standards has been set up in Pune with a focus on oral solids. API Centaur is India's largest manufacturer and exporter of Psychotropic API and have introduced 24 API for the first time in India. Our API manufacturing facility near Mumbai conforms to USFDA standards and our clientele includes Big Pharma, generic majors and Indian multinationals. Our specialisation ranges from API and intermediates to custom synthesis and process chemistry. An integrated approach ensures that we can scale up capabilities from conceptualisation to commercialisation. CRO A 10,000 square feet, ultra-modern, contract research organisation (CRO) with a 36 bed clinical pharmacology unit (CPU), has been set up at Centaur House, our corporate headquarters. Facilities include Bio-availability (BA), Bio-equivalence (BE), Bio-analysis & Clinical trials. State-of-the-art R&D laboratories dedicated to formulations and API, approved by the Government of India are also located at Centaur House. Future By strategically positioning itself for collaborative relationships, Centaur has tied up with the world's leading players, by offering high performance value options and critical capabilities. We believe that our core competencies in API, formulations, CRAM and CRO will enhance business volumes and help us ascend the pharmaceutical value chain. This would help us realise our vision of emerging as a 'fully integrated global pharmaceutical player'.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Resonance has been a presence in the API and Specialty Chemicals segment for more than 30 years. After a start in Mumbai, operations moved to Bangalore in 1984. In the 30 years, Resonance has partnered with several multinationals on custom synthesis projects and with our strengths in multi-step synthesis together with focus on quality, we have help...
Resonance has been a presence in the API and Specialty Chemicals segment for more than 30 years. After a start in Mumbai, operations moved to Bangalore in 1984. In the 30 years, Resonance has partnered with several multinationals on custom synthesis projects and with our strengths in multi-step synthesis together with focus on quality, we have helped our customers develop their products in a timely fashion. We have brought the same discipline to our API business and in the recent years have developed some complex molecules that are produced in our cGMP plant. Our facility is WHO GMP certified and we follow cGMP as per the ICH Q7 guideline.We have registered DMFs and CEPs for some of our products and are in the process of registering more. We currently sell to the European and other markets on the basis of our DMFs and CEPs.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Resonance has been a presence in the API and Specialty Chemicals segment for more than 30 years. After a start in Mumbai, operations moved to Bangalore in 1984. In the 30 years, Resonance has partnered with several multinationals on custom synthesis projects and with our strengths in multi-step synthesis together with focus on quality, we have help...
Resonance has been a presence in the API and Specialty Chemicals segment for more than 30 years. After a start in Mumbai, operations moved to Bangalore in 1984. In the 30 years, Resonance has partnered with several multinationals on custom synthesis projects and with our strengths in multi-step synthesis together with focus on quality, we have helped our customers develop their products in a timely fashion. We have brought the same discipline to our API business and in the recent years have developed some complex molecules that are produced in our cGMP plant. Our facility is WHO GMP certified and we follow cGMP as per the ICH Q7 guideline.We have registered DMFs and CEPs for some of our products and are in the process of registering more. We currently sell to the European and other markets on the basis of our DMFs and CEPs.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Holding the worldwide leading position in the production of Caffeine, Jilin Shulan Synthetic Pharmaceutical Co., Ltd. offer quality services to the pharmaceutical and soft drink industries.The major products we produce are Caffeine, Theophylline, Aminophylline, Theobromine, 8-Chlorotheophylline, all the products meet the latest compendial monograph...
Holding the worldwide leading position in the production of Caffeine, Jilin Shulan Synthetic Pharmaceutical Co., Ltd. offer quality services to the pharmaceutical and soft drink industries.The major products we produce are Caffeine, Theophylline, Aminophylline, Theobromine, 8-Chlorotheophylline, all the products meet the latest compendial monograph.We respect the spirit of GMP in the production and have obtained GMP certificate issued by the state Food and Drug Adiministration of China and also passed on-site inspection conducted by US FDA.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Established in 1943 as one of the national largest manufacturing and exporting bases in the chemical synthetic pharmaceuticals field, Shandong Xinhua Pharmaceutical Company Limited ("Shandong Xinhua") is in an leading position in the manufacturing technology and capacity for antipyretics and analgesics in China and is an important manufacturer in C...
Established in 1943 as one of the national largest manufacturing and exporting bases in the chemical synthetic pharmaceuticals field, Shandong Xinhua Pharmaceutical Company Limited ("Shandong Xinhua") is in an leading position in the manufacturing technology and capacity for antipyretics and analgesics in China and is an important manufacturer in China for the drugs for central nervous system, steroids, cardio cerebrovascular system as well as finished dosage forms and pharmaceutical intermediates. With implementing the global market development strategy and adopting the international advanced standards in quality management, Shandong Xinhua has been granted the certifications of GMP, ISO9001, ISO14001, ISO 10012, and ISO22000. The main products of Shandong Xinhua have been granted the COS Certificate from EDQM and passed the site inspection from USA FDA. By taking the advantages of its solid scientific research strength, well-established quality system, high market reputation as well as being a listing company of H shares and A shares with sound capital structure and product portfolio. "XINHUA" brand was honored with the title of "Chinese Famous Brand" in China. With the high commitment to the product quality and development of the international markets, the Company has established the strategic partnership with dozens of MNCs, the products of the Company has been distributed to more than 60 countries and regions.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Consistent growth and sustainability is a multidimensional aspiration for all at Macleods, we remained focused on providing quality and affordable medicines to billions of ailing patients across geographies and bridging the gap of unmet needs of medical fraternity through continuous innovation. Our basic business philosophy, by its very nature, ser...
Consistent growth and sustainability is a multidimensional aspiration for all at Macleods, we remained focused on providing quality and affordable medicines to billions of ailing patients across geographies and bridging the gap of unmet needs of medical fraternity through continuous innovation. Our basic business philosophy, by its very nature, serves a social responsibility hence we have a far better reason than profits alone to drive our performance. Sustainability, is not a trend we blindly follow, it is intrinsic to how we have operated since the genesis of the organization in the year 1986. Macleods is focused on increasing the momentum in the business through organic growth routes. Growth is well spread across geographies with focus on key therapeutics segments. We continue to evaluate various therapy areas to strengthen its business and competitiveness. Macleods has forayed into high growth potential segments like Cardiovascular, Diabetes, Orthopedics, Gynecology, Respiratory and Oncology. These new growth areas will add significant depth to the existing product pipeline. Macleods business has witnessed exemplary growth over the past few years growing ahead of the Indian Pharma Market as well as International market. The company has focused on gaining markets while maintaining its dominant position in Anti-TB and Anti-infective segments.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of Flag Korea, Republic Of


Post An Enquiry Post An Enquiry


Virtual Booth Virtual Booth

Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to g...
Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to general, special, and aseptic pharmaceuticals.On the other hands, JEIL is manufacturing FDF Products sold to Japan and other countries.With marketing strategy of 'First generic' and Innovative drug, JEIL have been extended the market in world-wide.

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of Flag Korea, Republic Of


Post An Enquiry Post An Enquiry


Virtual Booth Virtual Booth

Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to g...
Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to general, special, and aseptic pharmaceuticals.On the other hands, JEIL is manufacturing FDF Products sold to Japan and other countries.With marketing strategy of 'First generic' and Innovative drug, JEIL have been extended the market in world-wide.